You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Characteristic Unweighted, No. Weighteda
Age, mean, y 7,784 44.5 (43.8–45.2)
Sex
Male 3,704 48.5 (47.3–49.7)
Female 4,080 51.5 (50.3–52.7)
Race/ethnicity
Non-Hispanic white 2,882 65.5 (59.9–70.6)
Non-Hispanic black 1,606 10.9 (8.5–13.9)
Hispanic 2,111 15.2 (11.7–19.4)
Non-Hispanic other 1,185 8.4 (7.1–10.1)
Education level
High school diploma or less 3,247 33.4 (30.1–36.9)
Some college 2,447 33.3 (31.2–35.5)
College graduate or above 2,090 33.3 (29.4–37.5)
Marital status
Married or coupled 4,760 64.9 (62.7–67.0)
Widowed, divorced, or separated 1,387 15.3 (13.9–16.7)
Never married 1,637 19.8 (18.0–21.8)
Family income-to-poverty ratio
≤1.3 2,755 24.4 (21.4–27.6)
>1.3 to ≤1.85 1,082 11.7 (10.5–13.0)
>1.85 3,947 64.0 (60.2–67.6)
Moderately severe or severe depression 235 2.6 (2.2–3.1)
Binge drinking once a month or moreb 1,217 17.8 (16.1–19.5)
Prescription sleep aid use 267 4.3 (3.5–5.2)
Sleep duration, h
<6 862 9.0 (8.2–9.9)
6 to <7 1,571 18.5 (17.3–19.8)
7 to <8 2,135 30.4 (28.9–31.9)
8 to <9 2,112 28.6 (27.5–29.7)
≥9 1,104 13.5 (12.3–14.7)
Overall CVH score
Mean 6,985c 8.0 (7.9–8.1)
Ideal (5–7 components) 1,156 17.8 (16.3–19.4)
Intermediate (3–4 components) 2,947 42.1 (40.9–43.3)
Poor (0–2 components) 3,200 40.1 (38.4–41.9)

Table 1. Estimated Weighted Population Characteristics and Prevalence of Sleep and Cardiovascular Health Among US Adults Aged 20–75 (N = 7,784), National Health and Nutrition Examination Survey, 2013–2016

Abbreviations: CI, confidence interval; CVH, cardiovascular health.
a Values are percentage (95% confidence interval) unless otherwise indicated. Because of survey weighting, proportions differ from calculations based on the unweighted number. Percentages may not total to 100% because of rounding.
b Binge drinking was defined as more than 4 drinks per day for women or more than 5 drinks per day for men.
c Mean score excluded those who were missing 1 or more CVH components.

Table 2.  

Component Definitiona Weighted Sleep Duration, mean or % (95% CI) P Valueb
<6 h 6 to <7 h 7 to <8 h 8 to <9 h ≥9 h
Overall CVH scorec
Mean NA 7.4 (7.2–7.6) 7.9 (7.8–8.0) 8.2 (8.1–8.4) 8.1 (7.9–8.3) 7.7 (7.4–8.0) <.001
Ideal 5–7 11.1 (8.3–14.7) 17.9 (15.9–20.0) 19.1 (17.1–21.3) 20.1 (17.8–22.6) 15.5 (12.7–18.7) .01
Intermediate 3–4 41.2 (36.0–46.6) 41.5 (38.5–44.7) 43.6 (40.6–46.7) 41.9 (39.3–44.7) 41.0 (37.6–44.5)
Poor 0–2 47.8 (43.0–52.6) 40.6 (37.9–43.3) 37.3 (34.4–40.2) 38.0 (35.1–41.0) 43.6 (39.4–47.8)
Smoking
Ideal Never smoker or quit ≥12 months ago 47.9 (41.7–54.2) 56.0 (52.2–59.8) 63.2 (60.5–65.7) 60.3 (57.1–63.4) 57.0 (52.5–61.4) <.001
Intermediate Smoked ≥100 cigarettes and quit <12 months ago 21.6 (17.7–25.9) 21.6 (18.8–24.8) 22.0 (19.4–24.7) 23.7 (21.3–26.2) 19.2 (16.4–22.3)
Poor Current smoker 30.6 (25.6–36.1) 22.4(19.4–25.7) 14.9 (12.7–17.5) 16.0 (13.7–18.7) 23.8 (20.3–27.8)
Body mass index (kg weight/height in m2)
Mean NA 30.6 (30.1–31.1) 29.6 (29.0–3.2) 29.1 (28.6–29.5) 29.0 (38.4–29.5) 29.0 (28.4–29.7) <.001
Ideal <25.0 kg/m2 23.3 (19.3–27.8) 27.0 (23.9–30.4) 30.1 (27.6–32.8) 30.4 (26.5–34.6) 31.2 (27.3–35.3) .03
Intermediate 25.0–29.9 kg/m2 30.1 (26.0–34.7) 32.6 (29.6–35.7) 32.9 (30.1–35.9) 32.7 (30.2–35.3) 30.3 (27.0–33.9)
Poor ≥30.0 kg/m2 46.6 (41.6–51.6) 40.4 (37.0–43.8) 37.0 (34.2–39.8) 36.9 (33.2–40.8) 38.5 (34.0–43.3)
Dietd
Ideal 4–5 components 0 0 0 0 0.1 (0.0–0.6) .10
Intermediate 2–3 components 22.3 (17.2–28.3) 24.4 (21.2–28.0) 26.8 (23.9–29.9) 25.7 (22.7–28.9) 20.2 (17.4–23.2)
Poor 0–1 components 77.7 (71.7–82.8) 75.6 (72.0–78.8) 73.2 (70.1–76.1) 74.3 (71.1–77.3) 79.7 (76.6–82.5)
Physical activity, min/wk
Mean NA 168.9 (144.0–193.7) 165.9 (150.8–180.9) 165.6 (147.2–184.0) 171.8 (154.1–189.5) 166.6 (136.0–197.2) .98
Ideal ≥150 min moderate and/or vigorous or ≥75 min vigorous 34.0 (29.7–38.6) 39.1 (35.8–42.5) 43.1 (39.3–47.0) 41.9 (38.4–45.5) 37.2 (32.0–42.7) .03
Intermediate 1–149 min moderate and/or vigorous or 1–74 min vigorous 17.1 (14.3–20.3) 16.7 (13.9–20.0) 16.3 (14.2–18.7) 19.2 (17.0–21.7) 14.6 (11.7–18.1)
Poor None 49.0 (45.3–52.7) 44.2 (40.5–47.9) 40.6 (37.5–43.8) 38.9 (35.3–42.6) 48.2 (42.9–53.6)
Blood pressure, mm Hg
Systolic, mean NA 122.3 (120.7–123.8) 121.3 (120.2–122.4) 120.5 (119.6–121.4) 121.3 (120.4–122.2) 121.8 (120.3–123.2) .25
Diastolic, mean NA 71.9 (70.8–73.1) 70.9 (70.1–71.7) 70.6 (69.8–71.4) 70.5 (69.6–71.3) 70.3 (69.1–71.5) .16
Ideal <120/<80 untreated 43.7 (39.5–48.0) 44.0 (40.7–47.3) 47.1 (43.6–50.6) 46.7 (44.2–49.2) 42.0 (38.3–45.8) .24
Intermediate SBP 120–139 or DBP 80–89 or treated to goal 46.0 (41.6–50.5) 48.3 (45.2–51.5) 45.5 (42.1–49.0) 45.0 (42.7–47.2) 48.1 (43.4–52.8)
Poor SBP ≥140 or DBP ≥90 10.3 (7.1–14.8) 7.7 (6.2–9.6) 7.4 (6.3–8.7) 8.3 (6.7–10.3) 9.9 (7.0-13.9)
Total cholesterol, mg/dl
Mean NA 191.9 (187.6–196.3) 189.6 (186.6–192.7) 192.1 (190.0–194.2) 195.4 (192.1–198.7) 193.0 (188.5–197.4) .07
Ideal <200 untreated 50.6 (45.3–55.9) 55.4 (51.3–59.4) 50.1 (46.9–53.3) 49.0 (44.9–53.2) 48.6 (44.7–52.5) .02
Intermediate 200–239 or treated to goal 39.3 (34.5–44.4) 34.5 (30.9–38.1) 38.5 (35.1–42.1) 36.2 (33.0–39.5) 36.7 (32.3–41.3)
Poor ≥240 10.1 (8.3–12.4) 10.2 (8.2–12.5) 11.4 (9.5–13.5) 14.8 (12.7–17.1) 14.7 (11.5–18.6)
Hemoglobin A1c, %
Mean NA 5.7 (5.6–5.7) 5.6 (5.6–5.7) 5.5 (5.5–5.6) 5.6 (5.5–5.6) 5.6 (5.5–5.7) .01
Ideal <5.7 untreated 66.1 (61.1–70.9) 70.8 (67.8–73.7) 74.3 (71.6–76.8) 72.9 (70.1–75.5) 65.8 (59.7–71.4) .008
Intermediate 5.7–6.4 or treated to goal 30.2 (25.5–35.3) 26.0 (23.1–29.1) 23.2 (21.0–25.6) 24.5 (22.2–26.9) 30.8 (25.6–36.6)
Poor ≥6.5 3.7 (2.5–5.4) 3.2 (2.4–4.4) 2.5 (1.7–3.7) 2.6 (1.9–3.5) 3.4 (2.3–4.9)

Table 2. Weighted Mean and Population Prevalence of Overall CVH Score and Individual Components Stratified By Sleep Duration Among US Adults Aged 20–75 (N = 7,784), National Health and Nutrition Examination Survey, 2013–2016

Abbreviations: CI, confidence interval; CVH, cardiovascular health; DBP, diastolic blood pressure; NA, not applicable; SBP, systolic blood pressure.
a Component definitions and scoring used were those previously described by Lloyd-Jones et al. with modification of hemoglobin A1c as a proxy for fasting plasma glucose [13]. The specific definitions used in this analysis are presented.
b P value calculated from adjusted Wald or Pearson’s χ2 tests that were corrected for the survey design.
c The CVH score comprises 7 components: smoking, body mass index, diet, physical activity, blood pressure, total cholesterol, and hemoglobin A1c (used as a proxy for fasting plasma glucose) [13]. Each component was scored as ideal (2 points), intermediate (1 point), or poor (0 points) based on guidelines described by Lloyd-Jones et al [13]. The continuous overall CVH score was calculated by summing the 7 components scores. Ideal CVH was defined as meeting ideal criteria for 5 to 7 of the components.
d American Heart Association Healthy Diet Score includes ≥4.5 cups of fruits or vegetables a day; two 3.5-ounce servings of fish per week; ≥3 one-ounce equivalent servings of whole grains per day; <1,500 mg of sodium per day; ≤36 ounces of sugar-sweetened beverages per week.

Table 3.  

Sleep Duration, No. of Hours Model 1a Estimate (95% CI) Model 2b Estimate (95% CI) Model 3c Estimate (95% CI) Model 4d Estimate (95% CI)
Odds of ideal CVH    
<6 0.53 (0.39 to 0.72) 0.63 (0.45 to 0.87) 0.56 (0.41 to 0.77) 0.65 (0.47 to 0.90)
6 to <7 0.90 (0.76 to 1.07) 0.97 (0.80 to 1.18) 0.91 (0.76 to 1.09) 0.97 (0.80 to 1.19)
7 to <8 1 [Reference]
8 to < 9 1.03 (0.82 to 1.28) 0.95 (0.74 to 1.23) 1.04 (0.84 to 1.30) 0.96 (0.75 to 1.23)
≥9 0.75 (0.58 to 0.98) 0.70 (0.53 to 0.93) 0.78 (0.60 to 1.02) 0.72 (0.55 to 0.94)
Mean differences in CVH score, mean
<6 −0.80 (−1.04 to −0.55) −0.48 (−0.69 to −0.27) −0.69 (−0.94 to −0.45) −0.41 (−0.61 to −0.20)
6 to <7 −0.31 (−0.45 to −0.17) −0.21 (−0.34 to −0.08) −0.3 (−0.44 to −0.16) −0.2 (−0.33 to −0.06)
7 to <8 [Reference]
8 to < 9 −0.15 (−0.36 to 0.06) −0.18 (−0.39 to 0.03) −0.12 (−0.32 to 0.07) −0.16 (−0.36 to 0.03)
≥9 −0.51 (−0.78 to −0.24) −0.38 (−0.63 to −0.13) −0.45 (−0.70 to −0.19) −0.33 (−0.57 to −0.09)

Table 3. Association Between Sleep Duration Categories and Ideal CVH in Sequential Adjusted Logistic and Linear Regression Models Among US Adults Aged 20–75 (N = 7,784), National Health and Nutrition Examination Survey, 2013–2016 

Abbreviations: CI, confidence interval; CVH, cardiovascular health; OR, odds ratio.
a Model 1: Unadjusted.
b Model 2: Adjusted for demographic factors of weighted age quartiles, sex, race/ethnicity, education level, and family income-to-poverty ratio category.
c Model 3: Adjusted for social and clinical factors of depression status, binge alcohol use, and prescription sleep aid use.
d Model 4: Fully adjusted model including factors from Models 2 and 3.

CME / ABIM MOC

Association Between Sleep Duration and Ideal Cardiovascular Health Among U.S. Adults, National Health and Nutrition Examination Survey, 2013-2016

  • Authors: Rebecca E. Cash, PhD, MPH; Chloe M. Beverly Hery, MS; Ashish R. Panchal, MD, PhD; Julie K. Bower, PhD, MPH, FAHA
  • CME / ABIM MOC Released: 6/11/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/11/2021
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, cardiologists, sleep medicine specialists, and other physicians who treat and manage patients at risk for cardiovascular disease.

The goal of this activity is to evaluate the effects of sleep duration on the cardiovascular risk profile.

Upon completion of this activity, participants will be able to:

  • Assess the relationship between sleep duration and the risk for cardiovascular events
  • Distinguish the proportion of US adults getting the recommended hours of sleep
  • Analyze variables in the cardiovascular risk profile affected by sleep duration
  • Evaluate how sleep duration can affect the cardiovascular risk profile among adults


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Rebecca E. Cash, PhD, MPH

    Division of Epidemiology
    The Ohio State University College of Public Health
    Columbus, Ohio
    The National Registry of Emergency Medical Technicians
    Columbus, Ohio
    Department of Emergency Medicine
    Massachusetts General Hospital
    Boston, MA

    Disclosures

    Disclosure: Rebecca E. Cash, PhD, MPH, has disclosed no relevant financial relationships.

  • Chloe M. Beverly Hery, MS

    Division of Epidemiology
    The Ohio State University College of Public Health
    Columbus, Ohio

    Disclosures

    Disclosure: Chloe M. Beverly Hery, MS, has disclosed no relevant financial relationships.

  • Ashish R. Panchal, MD, PhD

    Division of Epidemiology
    The Ohio State University College of Public Health
    Columbus, Ohio
    The National Registry of Emergency Medical Technicians
    Columbus, Ohio
    Department of Emergency Medicine
    The Ohio State University Wexner Medical Center
    Columbus, Ohio

    Disclosures

    Disclosure: Ashish R. Panchal, MD, PhD, has disclosed no relevant financial relationships.

  • Julie K. Bower, PhD, MPH, FAHA

    Division of Epidemiology
    The Ohio State University College of Public Health
    Columbus, Ohio

    Disclosures

    Disclosure: Julie K. Bower, PhD, MPH, FAHA, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: Vertex Pharmaceuticals
    Employed by a commercial interest: Vertex Pharmaceuticals

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine, School of Medicine
    Irvine, California

    Disclosures

    Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Johnson & Johnson Pharmaceutical Research & Development, LLC; GlaxoSmithKline
    Served as a speaker or a member of a speakers bureau for: Genentech, GlaxoSmithKline

Editor

  • Rosemarie Perrin

    Editor, Preventing Chronic Disease

    Disclosures

    Disclosure: Rosemarie Perrin has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclose that they have no relevant financial relationships.


Accreditation Statements



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Preventing Chronic Disease. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™  . Physicians should claim only the credit commensurate with the extent of their participation in the activity

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Association Between Sleep Duration and Ideal Cardiovascular Health Among U.S. Adults, National Health and Nutrition Examination Survey, 2013-2016

Authors: Rebecca E. Cash, PhD, MPH; Chloe M. Beverly Hery, MS; Ashish R. Panchal, MD, PhD; Julie K. Bower, PhD, MPH, FAHAFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 6/11/2020

Valid for credit through: 6/11/2021

processing....

Summary

What is already known on this topic?

Short and long sleep durations are risk factors for cardiovascular disease, but limited work has assessed the association between sleep duration and cardiovascular health, a measure of the health of the cardiovascular system. Ideal cardiovascular health is associated with a reduced risk of developing cardiovascular disease.

What is added by this report?

By using a nationally representative sample of US adults from the National Health and Nutrition Examination Survey, we showed that very short (<6 h) and very long (≥9 h) sleep duration was significantly associated with decreased odds of ideal cardiovascular health and a significant decrease in mean cardiovascular health score.

What are the implications for public health practice?

Sleep may be an additional component to describe health of the cardiovascular system. Unhealthy sleep duration represents a modifiable risk factor that can be targeted for population-level intervention.

« Return to: Association Between Sleep Duration and Ideal Cardiovascular Health Among U.S. Adults, National Health and Nutrition Examination Survey, 2013-2016